Takeda Pharmaceutical Company Limited
4502
Classificação em ações
#377
Takeda Pharmaceutical Company Limited is a global biopharmaceutical enterprise... Takeda Pharmaceutical Company Limited is a global biopharmaceutical enterprise engaged in the discovery, development, manufacturing, marketing, and out-licensing of various medical products. The company's operations span Japan, the United States, Europe, Canada, Latin America, Russia, and other regions across Asia and internationally. Takeda concentrates its efforts on key therapeutic areas such as gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. Its extensive product range includes well-known brands like Entyvio, Takhzyro, Velcade, and Vyvanse. To advance its pipeline and innovation, Takeda actively fosters numerous collaborations, in-licensing agreements, research partnerships, and strategic alliances with a diverse array of organizations, including academic institutions like the University of Texas MD Anderson Cancer Center and biotech firms such as Neurocrine Biosciences, Inc. and Arrowhead Pharmaceuticals Inc. Established in 1781, the company maintains its headquarters in Tokyo, Japan.
Preço da ação
$40.31
Valor de mercado
$64.13B
Variação (1 dia)
0.82%
Variação (1 ano)
42.59%
País
JP
Negociar Takeda Pharmaceutical Company Limited (4502)
Categoria
Healthcare
EPS de Takeda Pharmaceutical Company Limited (4502)
EPS em 2026 TTM: 0
De acordo com os últimos relatórios financeiros e o preço das ações da Takeda Pharmaceutical Company Limited, o EPS atual da empresa (TTM) é 0. No final de 2026, a empresa teve um EPS de 0, igual a ao EPS de 2026, que foi de 0.
Histórico de EPS da Takeda Pharmaceutical Company Limited de 2026 até 2026
EPS no final de cada ano
| Ano | EPS | Alterar |
|---|---|---|
| Não há dados suficientes para as datas fornecidas. | ||
EPS de empresas semelhantes ou concorrentes
| Empresa | EPS | Diferença de EPS | País |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
CH
|
|
| $0.56 | - |
IN
|
|
| - | - |
CN
|
